We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
ZyVersa announced advancements in development of our lead inflammasome inhibitor candidate, IC 100. IC 100 is a novel monoclonal antibody that inhibits the ASC component of multiple types of inflammasomes...